CanniMed Therapeutics Inc. is a Canadian pharmaceutical company and leader in the medical cannabis industry with 15 years of experience cultivating cannabis. It has GMP-compliant production facilities and a clinical research program. CanniMed raised $69 million in its IPO to fund expansion and clinical trials to validate medical cannabis for pain relief. It focuses on pharmaceutical-grade products including cannabis oils to address the needs of the growing medical cannabis market and aging population seeking pain treatment alternatives.

1. International Biopharmaceutical Company and
Leader in Canadian Medical Cannabis
February 2017
Herbal
bottles

2. 2
Disclaimer
GENERAL
In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Capitalized terms that are not defined in this presentation have the meanings ascribed to them in the Prospectus. Any graphs, tables or other
information in this presentation demonstrating the historical performance of CanniMed Therapeutics Inc. (“the Company” or “CMED”) or any other entity contained in this presentation are intended only to illustrate past performance of
such entities and are not necessarily indicative of future performance of CMED or such entities.
FORWARD-LOOKING INFORMATION
This presentation contains “forward-looking information” within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future outlook and anticipated events or results and may include
information regarding our financial position, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, plans and objectives. Particularly, information regarding our expectations of future results,
performance, achievements, “EBITDA” profile accelerating towards near term breakeven, growth in the number of registered patients, prospects or opportunities or the markets in which we operates is forward-looking information. In
some cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “an opportunity exists”, “outlook”, “prospects”, “strategy”, “intends”,
“believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations,
intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s
expectations, estimates and projections regarding future events or circumstances.
Forward-looking information contained in this presentation and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions
and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be
no assurance that the underlying opinions, estimates and assumptions will prove to be correct.
Whether actual results, performance or achievements will conform to the Company’s expectations is subject to a number of known risks and uncertainties, including those listed under the heading “Risk Factors” in our prospectus dated
December 21, 2016 (available on sedar.com) and the risk that the Company will not reach breakeven within the timeframe anticipated and that the number of registered patients will not increase at the rate expected. Although we have
attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information in this presentation, there may be other risk factors not presently known to us or that
we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such
information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which
speaks only as of the date made. The forward-looking information contained in this presentation represents our expectations as of the date of this presentation or the date indicated, regardless of the time of delivery of the presentation.
However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws
in Canada.
An investment in our shares is subject to a number of risks that should be considered by a prospective purchaser. Prospective purchasers should carefully consider these risks with their investment advisor before purchasing shares of the
Company.
All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements. Investors should read the entire Prospectus and consult their own professional advisors to ascertain and
assess the income tax, legal, risk factors and other aspects of their investment in the shares.
NON-IFRS MEASURES AND INDUSTRY METRICS
This presentation makes reference to certain non-IFRS measures including “EBITDA”, and to certain operating metrics in the industry. Non-IFRS measures including industry metrics do not have a standardized meaning prescribed by IFRS
and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of
our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. Please refer to the Prospectus
for further details on these non-IFRS measures including industry metrics, including relevant definitions and reconciliations.

3. 3
Summary Overview
CanniMed Therapeutics Inc. (“CMED” or the “Company”) is a Canadian-based, international plant
biopharmaceutical company and a leader in the Canadian medical cannabis industry with 15
years’ of pharmaceutical cannabis cultivation experience, a state-of-the-art, GMP-compliant
production process including 281 points of quality control, and a world class research and
development platform, with a wide range of pharmaceutical-grade cannabis products.
CMED raised gross proceeds of $69 million in its IPO, including the over-allotment option which
closed in January, 20171.
(1) January, 2017: 24.8 MM diluted shares outstanding

4. 4
Pharmaceutical Cannabis – The Opportunity is Significant
Legislative and political environments are becoming
more favorable towards medical cannabis globally;
Canada is a leader
Commonly prescribed opioids have increased risk of
addiction, overdose and mortality
Increasing health care costs demonstrate a strong
need for alternative methods for pain management
Rapidly aging population seeking pain relief to maintain
an active lifestyle and manage end-of-life conditions





5. 5
Investor Highlights
Experienced LP with a 15 year history of growing
medical cannabis
Pharmaceutical focus; GMP-compliant production process;
investing in a clinical trial
Chronic pain costs more than $6 billion annually in Canada; issues with
existing treatments create significant opportunity for cannabis products
Positioned to address significant market opportunity with
baby boomers looking to maintain active lifestyles
EBITDA profile accelerating towards
near term breakeven
Strong management and board with broad experience in
cannabis, medical biotechnology, and pharmaceuticals







6. 6
100
1,000
10,000
100,000
1,000,000
10,000,000
2002 2005 2008 2011 2014 2017 2020 2023
CanadianMedicalCannabisUsers
MMAR
MMPR/ACMPR
Trendline - MMAR
Trendline - MMPR/ACMPR
Medical Cannabis is a Growth Market in Canada
Medical Marijuana Registered Patients(1) MMPR Total Volume Sales(2)
Q/Q growth in
Registered Patients
(1) Source: Health Canada and management estimates. Lower trend line (purple) extrapolated by statistical software based on
historical data. Upper trend line (blue) based on growth rate of lower trend line.
(2) Rolling 12 months. Shown as at the end of the reporting period. Includes wholesale sales.
31% 18% 61%Q/Q growth in Volumes Q/Q growth in Oil
Market growth is surpassing Heath Canada projections
Cannabis oils have
accelerated market growth
Projected
Health Canada
Projection:
450,000
MMPR
Introduction
Sept 2016:
98,460

7. 7
Physician Attitudes Shifting Towards Medical Cannabis
21%
52%
27%
(1) As reported by Legar Research Intelligence Group (2014 Survey) and Rogers Media (2016 Survey) through survey commissioned
by CanniMed Pharmaceuticals. Both surveys utilized the same questionnaire for comparability purposes. (2) Percentage of doctors
who have been approached by patients in the past 6 months
78%Doctors Approached(2)
Currently Prescribe
Interested in Prescribing
Will not Prescribe
(under any circumstances)
2016(1)2014(1)
32%Properly Informed
12%
52%
36%
48%
31%

8. 8
Medical Cannabis

9. 9
Broad Potential Benefits; Early Focus on Chronic Pain
(1) Various third-party studies. (2) As reported by Legar Research Intelligence Group through report commissioned in Sept 2016 by CanniMed.
• Various third-party studies suggest that medical cannabis has shown, or has potential to show,
efficacy in the treatment of a large number of medical conditions
Alzheimer’s Disease Slows formation of amyloid plaques by blocking enzymes in the brain
Anxiety Reduces agitation
Arthritis Reduces inflammation and pain
Brain injuries Reduces inflammation / swelling
Cancer (chemotherapy) Aids in pain management and enhances appetite; also shown to reduce
growth of some cancer cells
Chronic nausea Reduces nausea
Chronic pain Binds to receptors on nerves to relieve pain
Eating disorders Stimulates appetite
Epilepsy Controls seizures
Fibromyalgia Reduces inflammation and pain
Glaucoma Decrease pressure inside the eye
Hepatitis C Reduces treatment side effects such as nausea and muscle aches
HIV/AIDS Stimulates appetite
Migraines Reduces pain
Multiple Sclerosis Binds to receptors in the nerves and muscles to relieve pain
Muscle spasms Reduces inflammation and pain
Parkinson’s Reduces pain and tremors and improves sleep
PTSD Reduces flashbacks, agitation and nightmares
Prescribed Uses(2)Medical Condition Observed Medical Impact(1)
5%
5%
12%
19%
29%
33%
69%
69%
79%
79%
Multiple
Sclerosis
Other
Post-Traumatic
Stress Disorder
HIV/AIDS Pain
Anorexia
Nausea
Pallative
Cancer-Related
Pain
Neuropathic
Pain
Chronic Pain

10. 10
17.5
21.7
2010 2014
$193.2
$219.1
2010 2015
• Canadians spent $219 billion on health care in 2015(1)
– 78%(2) of emergency department visits are due to
pain
• One in five Canadian adults suffer from chronic pain(3)
• Chronic pain costs more than $6 billion annually(3)
– More than cancer, heart disease and HIV
combined
– Productivity losses estimated to increase costs to
more than $37 billion(3)
• Inadequate pain assessment and treatment is a
growing problem in Canada(4)
• Opioids are commonly prescribed for chronic pain
despite little evidence of long term efficacy(5) and an
elevated risk of addiction and overdose
– Canadian Federal Health Minister has called for a
reduction of opioid prescriptions
Pain Market is Large; Current Treatments are Inadequate
Heath Care Spending(1)
(1) National Health Expenditure Database. Canadian Institute for Health Information. (2) Canadian Pain Society. (3) Direct costs. Pain
Resource Centre, 2015: Pain in Canada Fact Sheet. (4) The Canadian Pain Society, 2011: Call to Action: The Need for a National Pain
Strategy for Canada. (5) Globe and Mail, October 2014; (6) Pain Physician Journal.
Opioid Prescriptions(6)
Medical cannabis may be a safe and effective alternative

11. 11
• With an aging population, the incidence of
chronic pain increases(2)
• Rate of opioid use as a pain reliever is highest
among seniors(3)
– 16% of seniors, as of 2013, use opioids(3)
• Baby boomers looking to manage pain and
maintain an active lifestyle are a significant
market opportunity for pharmaceutical-quality
cannabis products
• New delivery mechanisms such as cannabis oils
and gelcaps are ideally suited
– More traditional forms
– Easier to target symptoms and doses
– Avoid stigmas associated with smoking
Baby Boomers Are a Key Target Market
Canadian Population Demographics(1)
29%
(1) Statistics Canada. (2) Pain Resource Centre, 2015: Pain in Canada Fact
Sheet. (3) In 2013; Canadian Centre on Substance Abuse, July 2015.
of the
population
5,607,345
4,365,585
4,332,490
4,498,805
5,334,100
9,338,355
0 to 14 years
15 to 24 years
25 to 34 years
35 to 44 years
45 to 54 years
55 years and over

12. 12
• Cannabis remains a Schedule I drug in the U.S.
– 28 states and D.C. no longer prosecute
– Change to Schedule II required for
cannabis to be declared fit for medical use
• DEA to allow increased supply of medical
cannabis for research purposes
• CanniMed is in the process of applying to the
DEA for a license
– Production facility is expected to provide a
“first mover” advantage in providing
pharmaceutical-grade medical cannabis in
the US
• Several discussions for international
distribution of the Company’s products ongoing
– LOI with Creso Pharma
International Markets Offer Additional Opportunity
32%
161 MM
29%
89 MM
Population Aged
55Years and Older
(1) National Conference of State Legislators updated to reflect the results of the 2016 US election. States that are categorized as “Legal
for Medical Use with Varying Limits on Use and Dosage” have different parameters for what patient conditions may be prescribed
medical cannabis, as well as the form of cannabis and delivery method. US federal law outlaws all non-research related use of cannabis.
(2) US Census Bureau; 2015. (3) European Union; Eurostat 2015. (4) Pew Research Centre
United States(2) European Union(3)
US State Cannabis Legislation(1)
~ 10,000 baby boomers will turn 65, every day, each year from 2011 to 2030(4)
Washington
Oregon
California
Montana
Wyoming
Colorado
New Mexico
Idaho
Nevada
Utah
Arizona
North Dakota
South Dakota
Nebraska
Kansas
Oklahoma
Texas
Minnesota
Iowa
MIssouri
Arkansas
Louisiana Florida
Michigan
Wisconsin
Illinois
Tennessee
Missis-
sippi Alabama
Georgia
South
Carolina
North
Carolina
Virginia
Kentucky
New
York
Pennsylvania
Ohio
Indiana West
Virgina
RI
Maine
VT
NH
MA
CT
DEMD
NJ
Alaska
Hawaii
Legalized for Medical Use
Illegal
Legalized for Medical Use with
Varying Limits on Use and Dosage

13. 13
• Canadian-based plant biopharmaceutical company and a leader in the Canadian medical cannabis
industry
– 15 years’ pharmaceutical cannabis cultivation experience
– History as the sole supplier to Health Canada
– World class, international research and development platforms
• Focused on the development and production of pharmaceutical-grade cannabis products
– Good Manufacturing Practices(1) (“GMP”) compliant production with 281 points of quality control
– First Health Canada approved Phase IIA clinical trial
– Dosing, labeling and packaging similar to other pharmaceuticals
• A leader in the development of new delivery mechanisms with broader market appeal
– Cannabis oil gelcap production targeted for late 2016 or early 2017
CanniMed Therapeutics – Pharmaceutical Focus
CMED is focused on becoming the supplier of choice in the medical community and
with patients such as baby boomers who are looking for consistent, high quality
treatment alternatives in forms that more closely align to traditional methods
(1) GMP are standards and procedures that pharmaceutical companies must adhere to in manufacturing their products in North America; part
of quality assurance that ensures that drugs are consistently produced and controlled to meet quality standards

14. 14
• The Company expects to continue to invest
significant resources towards clinical trials focussed
on validating medical cannabis as a safe and
effective pain relief option
• $1 million invested in Health Canada-approved
“CAPRI Trial”(1)
– First Phase II Health Canada approved clinical
trial
– Randomized, double-blind, placebo controlled,
proof-of-concept Phase IIA clinical trial
– Seeks to examine the varying ratios of THC and
CBD to help determine whether high THC, high
CBD, or a combination of the two, has the
greatest impact on the treatment of
osteoarthritis of the knee
• Answering important questions that physicians and
other health care professionals have regarding
dosing, as well as short term safety and efficacy
relating to specific ratios of cannabinoids
Investing in Clinical Trials
(1) Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee

15. 15
State-of-the-Art, GMP-Compliant Production Facilities
INSERT Saskatoon GRAPHIC
Saskatoon, Saskatchewan
• 97,000 sq. ft. above-ground production facility
• 30 large individual biosecure growth chambers
• 7,000 kg of dried herbal capacity per annum
• State-of-the-art, GMP-compliant production process
– 281 points of quality control
• Five separate Level 7 security compliant vaults
• “Seventh Generation” facility(1)
White Pine, Michigan
• 19,000 sq. ft of underground growth
chambers currently under construction
• Supports BioProducts and BioPharm
divisions
• Additional 35 square mile underground
footprint
– Potential to support more
than 50,000 kg of herbal
capacity per annum
GMP
Standards
International Organization
for Standardization
(ISO)
Good Production Practices
(GPP)
Required
under
ACMPR
Required for
pharmaceutical
production
(1) Benefited from the technologies and innovations advanced over the course of seven distinct facility builds.
(2) Management estimates that, subject to the currently available power supply, of the approximately 35 square miles of underground
footprint available, approximately 600,000 to 800,000 square feet could feasibly be developed by it for production purposes.

16. 16
CanniMed Product Offering - Herbal
• Pharmaceutical quality and branding promotes doctor confidence and supports more effective
prescription dosages
– Identified by the percentage of THC and CBD they contain
– Each product is designed with specific benefits in mind to address each patient’s requirements
Colour and Name THC CBD
Purple 1·13 0.7% 13.0%
Red 4·10 4.0% 10.0%
Orange 9·9 9.0% 9.5%
Yellow 12·0 12.5% <0.5%
Green 15·5 15.0% 5.0%
Blue 17·1 17.0% 0.7%
Indigo 22·1 22.0% 0.7%

17. 17
• Cannabis oils are the preferred product for patients reluctant to smoke herbal product
– Ideal for palliative care and hospitalized patients
– Significant sales acceleration since launching oils in January
• Gelcaps are ideally suited for baby boomers looking for a safe, reliable way to manage their chronic pain
symptoms and maintain an active lifestyle
CanniMed Product Offering - Oils
Colour and Name THC (mg/ml) CBD (mg/ml) Total THC (mg) Total CBD (mg)
Purple 1·20 1.0 20.0 60 1,200
Orange 10·10 9.8 9.9 588 594
Blue 18·0 18.3 0.2 1,098 12
Cannabis Oil Gelcaps
Higher margin, value-added products with broader market appeal
Production trial
start early 2017

18. 18
10,224
17,000
Apr-16 Present
-
361.0
Q3 15 Q3 16
149.0
255.2
Q3 15 Q3 16
Growing Momentum
Patients Physicians
Total Dried Equivalents (KG)(1)
Oil Volume (L)
2,385
3,161
Apr-16 Present
(1) Includes both dried herbal and oils

19. 19
Strong Management Team and Board
Brent H. Zettl, B.S.A., President & CEO, Co-founder
• President of CanniMed since 1991
• Spearheaded the development activities of the innovative underground
growth chambers
• 2014 E&Y Entrepreneur of the Year for the Prairies Business-to-Consumer
category
John Knowles, CFO
• Over 30 years experience in senior executive and board roles in Canada
and internationally
• A Director of CanniMed for over eight years and past Chair of the Audit
and Finance Board Committee
• Former VP, CFO of Hudbay Minerals Inc., Executive VP of Aur Resources
Inc., and CEO of LiCo Energy Metals Inc.
Larry Holbrook, Ph.D., Chief Research Officer
• Background includes Senior Research Scientist positions with extensive
and diverse agricultural biotechnology experience in both government and
industrial settings
• Over 20 years of experience in basic research and applications to genetic
modification of crop plants
• Author or co-author on 40 publications and books
Gulwant Bajwa, VP, Business Development and Regulatory Affairs
• Previously with Health Canada as a Senior Program Manager in former
Bureau of Medical Cannabis and as a Policy Analyst in the Intellectual
Property and Technology Transfer office of Health Canada
• Five years as Director of Operations at JDS Uniphase Corporation
Donald Ching, LL.B, B.A. (Chairman)
• Director, Golden Opportunities Fund; Former President and CEO of SaskTel
Doug Banzet
• CFO and Director, Golden Opportunities Fund
Rob Duguid, B.B.A.
• Partner, PFM Capital; VP, Prairie Ventures Fund
Marianne Greer, Ph.D.
• Independent Pharmacist Consultant
Richard Hoyt, B.Sc.
• VP, Business Development, Mallinckrodt PLC
Dwayne L. Lashyn, B.Comm, C.A.
• VP, Quantico Capital Corp.
Bruce F. Mackler, Ph.D., J.D.
• Consultant in FDA, USDA and EPA Regulatory Processes
Brandon J. Price, Ph.D.
• Executive VP, Nascent Biotech; Co-founder, Biogenin
John L. Knowles, B.Comm, C.A.
• CFO, CanniMed Therapeutics Inc.
Brent Zettl
• President & CEO, CanniMed Therapeutics Inc.
Key Management Board of Directors

20. 20